RUXOLITINIB

ruxolitinib 15 mg tablet, 56

RUXOLITINIB (10615Q)

ruxolitinib 15 mg tablet, 56
10615Q
Body System:
Manner of administration:Oral
General Schedule
Authority Required (STREAMLINED)

Restriction  18324

Indication: High risk and intermediate-2 risk myelofibrosis
Treatment phase: Continuing treatment

Restriction  18241

Indication: Intermediate-1 risk myelofibrosis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 56 # of repeats: 5 DPMQ: $4,675.43 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Jakavi